Lyell Immunopharma (NASDAQ:LYEL) Shares Down 5.9% - Should You Sell?

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) traded down 5.9% during mid-day trading on Tuesday . The stock traded as low as $9.02 and last traded at $9.10. 36,808 shares changed hands during mid-day trading, a decline of 49% from the average session volume of 72,562 shares. The stock had previously closed at $9.67.

Wall Street Analysts Forecast Growth

LYEL has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of Lyell Immunopharma to a "hold" rating in a report on Friday, June 6th. HC Wainwright reaffirmed a "neutral" rating and issued a $10.00 price target on shares of Lyell Immunopharma in a research note on Tuesday, June 24th.

Lyell Immunopharma Stock Performance

The company's fifty day moving average is $9.30 and its two-hundred day moving average is $10.55. The company has a market cap of $136.84 million, a price-to-earnings ratio of -0.37 and a beta of -0.24.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($3.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.80) by $0.20. Lyell Immunopharma had a negative return on equity of 73.66% and a negative net margin of 514,649.22%. The firm had revenue of $0.01 million for the quarter. On average, sell-side analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

Large investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. lifted its position in shares of Lyell Immunopharma by 43.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,645,787 shares of the company's stock valued at $1,053,000 after acquiring an additional 498,417 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Lyell Immunopharma by 347.8% in the fourth quarter. JPMorgan Chase & Co. now owns 433,265 shares of the company's stock valued at $277,000 after acquiring an additional 336,516 shares in the last quarter. Takeda Pharmaceutical Co. Ltd. purchased a new stake in shares of Lyell Immunopharma in the fourth quarter valued at $527,000. Geode Capital Management LLC lifted its position in shares of Lyell Immunopharma by 2.9% in the fourth quarter. Geode Capital Management LLC now owns 4,137,264 shares of the company's stock valued at $2,648,000 after acquiring an additional 117,303 shares in the last quarter. Finally, RPO LLC purchased a new position in Lyell Immunopharma during the fourth quarter worth about $42,000. Hedge funds and other institutional investors own 66.05% of the company's stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.